Alzheimer Disease–Relevant Biomarker Elevations in Psychosis and Broad Neuropsychiatric Impairment

Michael J. C. Bray; Jacob S. Shaw; Christopher B. Morrow; Chiadi U. Onyike; Alzheimer’s Disease Neuroimaging Initiative; Michael W. Weiner; Paul Aisen; L. J. Thal; Clifford R. Jack; William Jagust; Susan Landau; Monica Rivera-Mindt; Steven Tam; Edward B. Lee; Edward B. Lee; Arthur W. Toga; Laurel Beckett; Danielle Harvey; Sungeun Kim; Andrew J. Saykin; Kwangslk Nho; Richard J. Perrin; Duygu Tosun; Pallavi Sachdev; Erin Drake; Dale Anders; Cat Conti; Rachel Nosheny; Diana Truran Sacrey; Juliet Fockler; Melanie J. Miller; Kaci Lacy; Chengshi Jin; Adam Diaz; Miriam T. Ashford; Derek Flenniken; Adrienne Kormos; Michael S. Rafii; REMA RAMAN; Chengshi Jin; Michael Donohue; Jennifer Salazar; Andrea Fidell; Virginia Boatwright; Justin Robison; Caileigh Zimmerman; Taylor Clanton; Sarah Walter; Taylor Clanton; Elizabeth Shaffer; Caitlin Webb; Lindsey Hergesheimer; Stephanie Smith; Sheila Ogwang; Olusegun Adegoke; Payam H. Mahboubi; Zoë Potter; Cecily Jenkins; Naomi Saito; Kedir Adem Hussen; Hannatu Amaza; M Nguyen Thao; Shaniya Parkins; Ombolanle Ayo; Matt Glittenberg; Kaori Kubo Germano; Joe Strong; Trinity Weisensel; Fabiola Magana; Lisa Thomas; Vanessa Guzmán; Adeyinka Ajayi; Joseph Di Benedetto; Sandra Talavera; Clifford R. Jack; Felmlee JP; Nick C. Fox; Paul Thompson; Charles DeCarli; Arvin Forghanian-Arani; Brett Borowski; Paul Aisen; Catie Hedberg; Chad Ward; Christopher Schwarz; Denise Alexandra Chavez Reyes; Jeff Gunter; John Moore-Weiss; Kejal Kantarci; Leonard Matoush; Matthew L. Senjem; Prashanthi Vemuri; Robert Reid; Ian B. Malone; Sophia I. Thomopoulos; Talia M. Nir; Neda Jahanshad; Evan Fletcher; Evan Fletcher; Stephanie R Chen

doi:10.1001/jamapsychiatry.2025.4347

January 21, 2026JAMA Psychiatry

Alzheimer Disease–Relevant Biomarker Elevations in Psychosis and Broad Neuropsychiatric Impairment

View at Publisher

Ask AI

Bookmark

Share

Key Points

This research aims to explore how specific serum biomarkers relate to psychosis in Alzheimer disease.
Cohort study design
Analysis of serum concentrations of hyperphosphorylated tau and neurofilament light chain
Focus on patients with psychosis and neuropsychiatric impairment
Elevated levels of hyperphosphorylated tau are associated with psychosis
Neurofilament light chain concentrations correlate with broader neuropsychiatric impairment in Alzheimer disease

Implication

Cohort study shows association of biomarkers with psychosis in Alzheimer disease, indicating disease complexity.

Abstract

This cohort study examines the association of serum hyperphosphorylated tau and neurofilament light chain concentrations with psychosis in Alzheimer disease.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bray et al. (2026) studied this question.

synapsesocial.com/papers/69731005c8125b09b0d1fb07 https://doi.org/10.1001/jamapsychiatry.2025.4347

View at Publisher

Ask AI

Bookmark

Share

Alzheimer Disease–Relevant Biomarker Elevations in Psychosis and Broad Neuropsychiatric Impairment

Key Points

Implication

Abstract

Discussion

Cite This Study

Alzheimer Disease–Relevant Biomarker Elevations in Psychosis and Broad Neuropsychiatric Impairment

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from JAMA Psychiatry

Keep reading

More related papers

More from JAMA Psychiatry